Brought to you by 
AbbVie pays $20bn in cash and stock for Pharmacyclics
10 May 2023
Executive Summary
AbbVie Inc. is buying Pharmacyclics Inc. for $261.25 per share (a 31% premium) in cash (58%) and AbbVie equity (42%), valuing the transaction at $20bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie pays $20bn in cash and stock for Pharmacyclics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice